BriaCell Prices Public Offering at $5.59 per Unit, Raising $30 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Offering Size: BriaCell Therapeutics announced a public offering of 5,366,726 units priced at $5.59 each, aiming to raise approximately $30 million to fund working capital and advance business objectives.
- Warrant Listing: The warrants included in the offering have been approved for listing on Nasdaq and are expected to begin trading on January 14, 2026, with an exercise price of $6.93 per share, which is likely to bolster investor confidence in the company's growth prospects.
- Closing Timeline: The public offering is expected to close on January 15, 2026, subject to customary closing conditions, reflecting the company's active engagement in capital markets and its financing capabilities.
- Compliance Assurance: BriaCell is relying on the exemption set forth in Section 602.1 of the TSX Company Manual, ensuring that its transactions on Nasdaq comply with relevant regulations, thereby enhancing its compliance and transparency in international markets.
Analyst Views on BCTX
Wall Street analysts forecast BCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCTX is 39.90 USD with a low forecast of 39.90 USD and a high forecast of 39.90 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.640
Low
39.90
Averages
39.90
High
39.90
Current: 7.640
Low
39.90
Averages
39.90
High
39.90
About BCTX
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
